After Hours
There may be slightly higher risks associated with pre-market and after-hours trading than during regular market hours. Due to the fact that issuers often announce critical financial information outside of regular trading hours, extended-hours trading may result in wider spreads for particular securities.
Stocks Info
As a NASDAQ listed company, AKBA falls under the Healthcare sector while operating within the Drug Manufacturers – Specialty & Generic industry segment. The current market capitalization of Akebia Therapeutics Inc is $861.72M. A total of 3.69 million shares were traded on the day, compared to an average of 4.78M shares.
In the most recent transaction, Ostrowski Erik sold 41,314 shares of AKBA for 3.67 per share on Jun 30 ’25. After the transaction, the SVP, CFO, CBO & Treasurer now owns 503,586 company shares. In a previous transaction on Jun 30 ’25, Ostrowski Erik bought 41,314 shares at 3.67 per share.
Among the insiders who sold shares, Malabre Richard C disposed of 15,000 shares on Jun 09 ’25 at a per-share price of $4.01. This resulted in the SVP, Chief Accounting Officer holding 266,914 shares of AKBA after the transaction. In another insider transaction, Malabre Richard C sold 13,334 shares at $3.53 per share on Jun 04 ’25. Company shares held by the SVP, Chief Accounting Officer now total 266,914.
In spite of price targets being rarely accurate, it tends to exert some kind influence from time to time, and was often accepted by the market as having some value. In terms of 52-week highs and lows, AKBA has a high of $4.08 and a low of $1.24.
As of this writing, AKBA has an earnings estimate of -$0.02 per share for the current quarter. EPS was calculated based on a consensus of 2.0 estimates, with a high estimate of -$0.02 per share and a lower estimate of -$0.02. The company reported an EPS of -$0.1 in the last quarter
Balance Sheet Annually/Quarterly
The balance sheet of a company shows what assets and liabilities a company has, as well as the amount, equity investors have invested. With the help of this information, a company’s financial ratios can be calculated to give investors an overview of the company’s prospects. AKBA’s latest balance sheet shows that the firm has $149.80M in Cash & Short Term Investments as of fiscal 2021. There were $136.05M in debt and $261.05M in liabilities at the time. Its Book Value Per Share was $0.11, while its Total Shareholder’s Equity was $74.01M.
Analysts Opinion
The risks associated with pre-market and after-hours trading may be slightly higher than the regular market hours. The reason is that extended-hours trading may result in wider spreads for particular security due to lower liquidity and higher volatility as issuers often announce critical financial information outside regular trading hours. Currently, 0 analysts are providing their opinions on the stock. On a scale of 1 to 5, with 1 being Sell and 5 being Buy, the average analyst rating for AKBA is Buy with a score of 5.00.
